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Background: The Maillard reaction is a chemical reaction occurring between a reducing sugar and an amino acid,
generally requiring thermal processing. Maillard reaction products (MRPs) have antioxidant, antimutagenic, and
antibacterial effects though 2,4-bis (p-hydroxyphenyl)-2-butenal (HPB242), a fructose-tyrosine MRP, appears to
inhibit proliferation of cancer cells, its mechanism of action has not been studied in detail. The purpose of this study
was to investigate the anti-proliferative effects of 2,4-bis (p-hydroxyphenyl)-2-butenal (HPB242) on two oral
squamous cell carcinoma (OSCC) cell lines, HN22 and HSC4, through regulation of specificity protein 1 (Sp1).
Results: HPB242 treatment dramatically reduced the cell growth rate and apoptotic cell morphologies. Sp1 was
significantly inhibited by HPB242 in a dose-dependent manner. Furthermore, cell cycle regulating proteins and
anti-apoptotic proteins, which are known as Sp1 target genes, were altered at the molecular levels. The key
important regulators in the cell cycle such as p27 were increased, whereas cell proliferation- and survival-related
proteins such as cyclin D1, myeloid leukemia sequence 1 (Mcl-1) and survivin were significantly decreased by HPB242
or suppressed Sp1 levels, however pro-apoptotic proteins caspase3 and PARP were cleaved in HN22 and HSC4.
Conclusions: HPB242 may be useful as a chemotherapeutic agent for OSCC for the purpose of treatment and
prevention of oral cancer and for the improvement of clinical outcomes.
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OncologyBackground
Oral squamous cell carcinoma (OSCC) is a common
type of malignant tumor. New cases of oral cancer occur
at around 275,000 patients, and OSCCs cases comprise
approximately >90% of diagnosed patients with oral can-
cer [1]. Although conservative treatments of oral cancer,
including surgery, radiation and chemotherapy, have well
advanced to date, the five-year survival rate still remains
to be less than 50% [2]. Oral cancer is a serious health
problem in many parts of the world and is the eighth-
leading cause of cancer-related death in men. Certain* Correspondence: s1004jh@gmail.com
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stated.studies have proposed that some of the risk factors for oral
cancer are tobacco, alcohol, ultraviolet light and oral le-
sions [3]. Although the occurrence of oral cancer is low,
the development of more effective therapeutic strategies
for the prevention and treatment of oral cancer is impera-
tive. Several studies have reported that novel plant-derived
compounds act as antitumor agents through modulation
of biological pathways [4].
Maillard Reaction Products (MRPs) such as Glucose-
tyrosine (Glu-Tyr) and Xylose-arginine (Xyl-Arg) have
antioxidant, antimutagenic, and antibacterial effects [5,6]
and the MR is one of the most common and complex
reactions that takes place mainly in foods during thermal
processing [7]. Also many studies have reported benefi-
cial effects associated with maillard reaction products,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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tensive, anticarcinogenic, and antimutagenic properties
[10-12]. However, to date, little is known about other
biological effects of MRPs. In this study, we examined
whether the fructose-tyrosine MRP, HPB242, could modu-
late cell cycle progression and Specificity protein (Sp) re-
pression, and thus induce apoptotic cell death of OSCCs.
Sp is a transcription factor and universally expressed
in all mammalian cells [13]. Specificity protein 1 (Sp1)
was recently defined as the Sp/krűppel-like transcription
factor [14] and was identified to play a significant role in
various physiological processes such as cell cycle regula-
tion, apoptosis and angiogenesis [15-18]. Furthermore,
Sp1 is highly expressed in various cancers such as breast
carcinoma, thyroid cancer, hepatocellular carcinoma,
pancreatic cancer, colorectal cancer, gastric cancer, cer-
vical cancer and lung cancer [16,18-21]. Regarding its
cancer-related functions, Sp1 has been suggested to be a
novel target for cancer therapy.
To characterize the effect of 2,4-bis (p-hydroxyphe-
nyl)-2-butenal (HPB242) on OSCCs, this study specific-
ally examined the anti-cancer effect of HPB242 on cell
viability against two oral squamous cell carcinoma cell
lines, HN22 and HSC4, and identified regulated proteins
by HPB242 treatment in the cells.
In this study, we investigated whether downstream
proteins of Sp1 protein and key apoptotic proteins could
be affected in their expression toward apoptotic cell
death through alteration of Sp1 expression by HPB242
treatment. Our results provide evidence for the chemo-
therapeutic efficacy of HPB242 in oral squamous cells.
Methods
Cell culture
HN22 and HSC4 cells, a type of human oral squamous
cancer cells, were obtained from Dankook University
(Cheonan) and Hokkaido University (Hokkaido) re-
spectively. HN22 and HSC4 were cultured in Hyclone
Dulbecco’s modified Eagle’s medium (DMEM) containing
10% heat-inactivated fetal bovine serum and 100 U/ml
each of penicillin and streptomycin at 37°C with 5% CO2
in humidified air.
Cell viability assay
Cell viability of HN22 and HSC4 cells was accessed
using the trypan blue dye exclusion method [22,23].
Briefly, both HN22 and HSC4 cells were seeded on a
6-well microtiter plate (5 × 104 cells/well), after which
they were treated with different doses of 5, 10, 15 and
20 μg/ml HPB242 for 24 hours and 48 hours. The HN22
and HSC4 cells treated with HPB242 were harvested by
trypsinization and washed in cultured media. Trypan
blue (0.4%) was added to treated cells, and after 5 min,
cells were loaded into a hemocytometer and counted.The number of viable cells was calculated as percent of
the total cell population.
DAPI staining
The number of undergoing apoptotic cells by HPB242 was
quantified using 4′-6-diamidino-2-phenylindole (DAPI)
staining. Nuclear condensation and fragmentation were
determined by DAPI stained nucleic acid. After 48 hours
post-treatment of the agent with different doses (HPB242;
5, 10, and 20 μg/ml), HN22 and HSC4 cells were har-
vested by trypsinization, washed with cold phosphate buff-
ered saline (PBS), and fixed in 100% methanol at room
temperature for 20 minutes. The cells were spread on a
slide and then stained with DAPI (2 μg/ml), and subse-
quently monitored by a FluoView confocal laser micro-
scope (Fluoview FV10i, Olympus Corporation, Tokyo).
Propidium iodide staining
After 48 hours of HPB242 treatment in HN22 and HSC4
cells, the cells were washed with cold PBS, pooled and cen-
trifuged before being fixed in 70% ice-cold ethanol over-
night at −20°C, and then treated with 150 μg/ml RNase A
and 20 μg/ml propidium iodide (PI; Sigma-Aldrich, Inc. St.
Louis, Missouri). The stained cells were analyzed, and the
distribution of the cells in different phases of the cell cycle
was calculated using flow cytometry with a MACSQuant
Analyzer (Miltenyi Biotec GmbH, Bergisch Gladbach).
Reverse transcription-polymerase chain reaction
Total RNA was extracted from the cells using TRIzol®
Reagent (Life Technologies, Carlsbad, California), and
2 μg of RNA was used to synthesize cDNA using the
HelixCript™ 1st-strand cDNA synthesis kit (NanoHelix,
Korea). cDNA was obtained by PCR using β-actin-specific
and Sp1-specific primers as described below under follow-
ing PCR conditions (35 cycles: 1 min at 95°C, 1 min at
56°C, and 1 min at 72°C). The β-actin primers used were;
forward 5′ GTG GGG CGC CCC AGG CAC CA 3′ and
reverse 5′ CTC CTT AAT GTC ACG CAC GAT TTC 3′;
and the Sp1 primers were; forward 5′ ATG CCT AAT
ATT CAG TAT CAA GTA 3′ and reverse 5′ CCC TGA
GGT GAC AGG CTG TGA 3′. PCR products were ana-
lyzed by 1% agarose gel electrophoresis.
Western blot analysis
Total cell lysate was prepared using PRO-PREP™ Protein
Extraction Solution (iNtRON Biotechnology, Korea)
containing 1 μg/ml aprotinin, 1 μg/ml leupeptin, and
1 mM PMSF. Fifty micrograms of total protein was sepa-
rated via 10 or 15% (v/v) SDS-polyacrylamide gel elec-
trophoresis and then transferred onto polyvinylidene
difluoride (PVDF) membranes. After blocking for two
hours at room temperature with 5% non-fat dried milk in
PBST containing 0.1% tween-20, the membranes were
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(1C6), p27 (C-19), Cyclin D1 (M-20) (Santa Cruz Biotech-
nology, Santa Cruz, CA), PARP (BD Biosciences, San Diego,
CA), Mcl-1, Survivin, Cleaved-caspase3, anti-Bid, anti-Bax,
anti-Bcl-xl (Cell Signaling, Danvers, MA) and β-actin
(AC-74) (Sigma-Aldrich) overnight at 4°C. After washing
with PBST, secondary antibodies to IgG (Santa Cruz Bio-
technology) conjugated with horseradish peroxidase were
used, and chemiluminescence signals were enhanced with
the Pierce ECL Western Blotting Substrate (Thermo scien-
tific, Rockford) according to the manufacturer’s instructions.
Immunocytochemistry analysis
The cells were seeded over each sterilized glass coverslips
on six-well tissue culture plates for 24 hours and incubated
with HPB242 for 48 hours. The cells were fixed and perme-
abilized with Cytofix/cytoperm solution for 30 min. For Sp1
and Cleaved-caspase3 expression, the cells were blocked
with 1% BSA and then incubated with monoclonal Sp1 and
Cleaved-caspase3 antibody at 4°C overnight. After washing
with PBST solution, the Sp1 and Cleaved-caspase3 antibody
was reacted with a Jackson 488- and 647-conjugated anti-
mouse secondary antibody at room temperature for 1 h
and then mounted with Mountin solution-VECTSHIELD
mounting medium for fluorescence with DAPI (Vector La-
boratories, Inc. Burlingame, CA) onto the cells. The cells
were visualized using a FluoView confocal laser microscope.Figure 1 The effect of HPB242 on cell viability of oral cancer cells. (A)
on HN22 and HSC4 cells. HN22 cells (2 × 103 cells/well) and HSC4 (3 × 103
hours and 48 hours with increasing concentrations of HPB242 in 10% FBS-D
method, as described under Methods. Results are indicated as cell viability re
from three independent experiments. The asterisk indicates a significant differ
(C) Morphological changes observed in the HPB242 treated (5, 10, and 20 μgStatistical analysis
Data are reported as the mean ± SD of at least three in-
dependent experiments. Statistical significance was eval-
uated using Student’s t-test. Compared to the vehicle
control, p < 0.05 were considered significant.
Results
Growth inhibition effects of HPB242 on OSCCs
To determine the effect of HPB242 on the cell viability
of two OSCCs, HN22 and HSC4, we confirmed the growth
inhibitory potential by trypan blue assay. The results indi-
cated that HPB242 decreased the viability of HN22 and
HSC4 cells in a dose-and time-dependent for 24 and 48
hours (Figure 1B). The IC50 value of HPB242 for 48 hours
of incubation was estimated as 9.96 μg/ml in HN22 and
9.85 μg/ml in HSC4 cells, respectively. The cell viabilities
of HN22 were shown as 78 ± 0.3%, 49.8 ± 1.2%, 37.5 ±
0.8%, and 23.8 ± 0.5% at 5, 10, 15, and 20 μg/ml of
HPB242, respectively, compared with untreated control
cells when viabilities were calculated at 48 hours post-
treatment. In the case of HSC4, viabilities were measured
as 66.7 ± 0.9%, 49.5 ± 0.5, 36.7 ± 0.6%, and 22.9 ± 1.0% at 5,
10, 15, and 20 μg/ml of HPB242, respectively, compared
to that of untreated control cells when viabilities were
calculated at 48 hours post-treatment. Apoptosis-
induced changes in the cell morphology in the
HPB242-containing medium were observed. After 48Chemical structure of HPB242. (B) The cell viability effect of HPB242
cells/well) cells were seeded in 96-well plates and incubated for 24
MEM. Cell viability was estimated using the trypan blue dye exclusion
lative to the untreated HPB242, and data are represented as means ± SD
ence compared to the negative control (untreated cells) (*p < 0.05).
/ml) or untreated HN22 and HSC4 cells 48 hours post-treatment.
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cytoplasmic blebbing and irregularities in shape,
indicating a sharp increase in the apoptosis of HPB242-
treated HN22 and HSC4 cells in a concentration-
dependent manner (Figure 1C).HPB242 treatments induces apoptosis of OSCCs
The effect of HPB242 treatment on initiation was due to
the induction of apoptotic cell death by nuclear morph-
ology using DAPI staining, which allowed visualization
of nuclear shrinkage and fragmentation. HPB242 treat-
ment of HN22 and HSC4 cells led to an increase in nu-
clear condensation and fragmentation compared to the
control group (Figure 2A, B). In order to determine
whether Sub-G1 population induction by HPB242 is re-
lated to apoptosis, HPB242 treated cells were markedFigure 2 The apoptotic effect induced by HPB242 in HN22 and HSC4
untreated for 48 hours. The cells were harvested and prepared for DAPI sta
of DNA fragmentation and nuclear condensation by fluorescence microsco
cells. (B) DNA fragmentation and nuclear condensation were quantified, an
Representative histograms of Sub-G1 population. HPB242-treated cells were
triplicate samples from three independent experiments. The asterisks (*) indwith PI staining. When HN22 and HSC4 cells were
treated with HPB242, an increased number of cells in
the Sub-G1 population was observed in 3.6 - 34% of
HPB242-treated HN22 cells and in 5.6 – 30.4% of
HPB242-treated HSC4 cells (Figure 2C, D).Specificity protein 1 protein is suppress by HPB242
Several studies have recognized that the expression levels
of transcription factor Sp1 dramatically increases during
transformation, representing a critical effect in tumor de-
velopment or maintenance. The effects of HPB242 treat-
ment on Sp1 levels were inspected by western blotting. As
shown in Figure 3A, HPB242 treatment led to a sharp de-
crease in the level of Sp1 in HN22 and HSC4 cells at 48
hours after treatment. In order to characterize the apop-
totic action of HPB242, we confirmed expression levels ofcells. Cells were incubated with HPB242 (5, 10, and 20 μg/ml) and
ining and PI staining as described in the Methods section. (A) Analysis
py (magnification ×600) after HPB242 treatment in HN22 and HSC4
d the results in triplicate are expressed as the mean ± SD. (C and D)
compared with untreated cells, and data are shown as the average of
icates p < 0.05 versus control cells.
Figure 3 (See legend on next page.)
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Figure 3 The effect of HPB242 on specificity protein 1 (Sp1) protein expression in HN22 and HSC4 cells. HN22 and HSC4 cells were
incubated with different concentrations of HPB242 for 48 hours. The cells were harvested and prepared for western blots as described under
Methods. Protein expression levels of Sp1 were detected using a specific antibody against Sp1, and its levels were quantified after actin
normalization. (A) The HPB242-treated cells were compared with untreated cells, and data are shown as the means ± SD of three independent
experiments. The asterisk indicates a significant difference compared with the negative control (untreated cells) (*p < 0.05). (B) Time-dependent
effects of HPB242 on Sp1 and Cleaved-caspase3 expression were performed in HN22 and HSC4 cells for 48 hours with 6 hours intervals. (C) The
effect of HPB242 (0–20 μg/ml) for 48 hours on Sp1 mRNA expression was determined by RT-PCR. The graphs indicate the ratio of Sp1 to β-actin
expression. (D) The effect of HPB242 on Sp1 protein turnover in HN22 and HSC4 cells. The protein lysates were obtained from cells pretreated
with protein synthesis inhibitor such as cycloheximide (CHX) for 2 hour and then exposed to HPB242 for 48 hours. The protein expression of Sp1
was analyzed by western blot analysis. (E) Immunocytochemistry analysis was performed in HPB242 treated HN22 and HSC4 cells. HN22 and
HSC4 cells were treated with different concentrations of HPB242 for 48 hours, and cells were immunostained with Sp1 specific antibody,
Cleaved-caspase3 specific antibody, and then signals were detected with Jackson 488- and 647-conjugated anti-mouse secondary antibody. DAPI
was used for nucleus staining. 254×190 mm (96 × 96 DPI).
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ever, Sp1 mRNA levels did not suppressed by HPB242 in
both HN22 and HSC4 cells (Figure 3C). When CHX-
pretreated HN22 and HSC4 cells were incubated with
HPB242, degradation of Sp1 protein by HPB242 was add-
itionally enhanced (Figure 3D). There were increases in
Cleaved-caspase3 following HPB242 (20 μg/ml) treatment
of HN22 and HSC4 cells in a time-dependent manner.
According to these observations, immunocytochemical
results also showed decreased levels of Sp1 positive cells
in a dose-dependent manner in HN22 and HSC4 cells
(Figure 3E). HPB242 also cell cycle arrest-related proteins
such as p27 were increased, whereas cell proliferation-
and survival-related proteins such as cyclin D1, Mcl-1 and
survivin were significantly decreased (Figure 4A, B). These
results collectively suggest that down-regulation of Sp1 by
HPB242 treatment could lead to apoptotic cell death.
HPB242 regulate the expression of anti-apoptotic and
apoptotic molecules in OSCCs
Treatment of cells with HPB242 regulates the expres-
sion levels of various apoptotic proteins (Figure 5A, B).Figure 4 The effect of HPB242 on downstream target proteins by the
incubated with HPB242 (0, 5, 10 and 20 μg/ml) for 48 h. The effect of HPB2
by Western blots. Fifty micrograms of cellular extract per lane was separate
protein was confirmed by incubating the same membrane with anti-β-ActiAn immunoblotting technique was used to analyze the
levels of several pro- and anti-apoptotic proteins to de-
termine whether treatment with HPB242 regulates the
expression of apoptosis-related proteins in HN22 and
HSC4 cells. Activated Bid, PARP, and Bcl-xl were de-
creased and Bax, Cleaved-PARP and Cleaved-caspase3
increased in HPB242-treated HN22 and HSC4 cells.
Discussion
MRPs such as Glu-Tyr and Xyl-Arg have antioxidant,
antimutagenic, and antibacterial effects [24]. Although
HPB242, a fructose-tyrosine MRP, appears to inhibit pro-
liferation of cancer cells, its mechanism of action has not
been studied in detail.
In this study, our findings along with the findings of pre-
vious research, HPB242 may induce apoptosis in OSCCs.
In the present study, the apoptotic effects of HPB242 on
HN22 and HSC4 cells were investigated through the try-
pan blue dye exclusion method. This assay, a traditional
method for discovering anticancer drugs, can be used to
determine the cytotoxic effect and proliferation of cell
lines [25,26]. In this study, this assay was used to elucidatespecificity protein 1 (Sp1). HN22 (A) and HSC4 (B) cells were
42 for 48 hours on p27, Cyclin D1, Mcl-1, and Survivin was determined
d on an SDS-PAGE gel as described in Methods. Equal loading of
n antibody.
Figure 5 The effect of HPB242 on apoptosis of HN22 and HSC4 cells. HN22 (A) and HSC4 (B) cells were incubated with HPB242 (0, 5, 10 and
20 μg/ml) for 48 h. Fifty micrograms of cellular extract per lane was separated on an SDS-PAGE gel as described in Methods. Immunoblot detection of
Bid, Cleaved-caspase3, and PARP, upregulation of Bax, downregulation of Bcl-xl in whole cell lysates from various concentration HPB242-treated HN22
and HSC4 cells for 48 hours. Equal loading of protein was confirmed by incubating the same membrane with anti-β-Actin antibody.
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(Figure 1). As shown in Figure 2, HPB242 inhibited the
proliferation of HN22 and HSC4 cells through cell cycle
arrest at G0/G1 and induction of apoptosis.
Transcription factor Sp1 is known to be regulated by
molecular target genes in various biological processes in-
cluding differentiation, metabolism, cell growth, angio-
genesis and apoptosis [13]. Therefore, Sp1 protein levels
are expected to be a negative prognostic factor and a po-
tential therapeutic target for cancer chemotherapy [27].
As shown in Figure 3A, B, treatment with HPB242 in-
duced a significant decrease in the protein expression
levels of Sp1 in the HN22 and HSC4 cells in a dose- and
time-dependent manner. However, Sp1 mRNA did not
suppressed by HPB242 in both HN22 and HSC4 cells
(Figure 3C). When CHX-pretreated HN22 and HSC4 cells
were incubated with HPB242, degradation of Sp1 protein
by HPB242 was additionally enhanced (Figure 3D). Im-
munocytochemistry results also revealed a decreased level
of Sp1 and an increased level of Cleaved-caspase3 in a
dose-dependent manner in the HN22 and HSC4 cell lines
(Figure 3E).
Our results confirmed that HPB242 induced nuclear
condensation and apoptosis of HN22 and HSC4 cells and
inhibit the expression of Sp1 and Sp1 regulatory proteins.
In a previous study, HPB242 inhibited cell viability and in-
duced apoptotic cell death in HN22 and HSC4 cells [13].
In addition, HPB242 inhibited the transcriptional activity
and expression of Sp1 downstream proteins, including p27,
Cyclin D1, Mcl-1 and Survivin, in a dose-dependent
manner (Figure 4). HPB242 reduced Bid and Bcl-xl,increased Bax, and activated Caspase3 and PARP, sug-
gesting that HPB242 regulates Sp1 and ultimately leads
to apoptotic cell death (Figure 5). Our results demon-
strate Sp1 could serve as an efficient therapeutic target
of cancer. Sp1 expression levels increase during trans-
formation, which can play a critical role in tumor devel-
opment or maintenance. Although Sp1 deregulation is
beneficial for treating tumor cells, it is reported that
overexpression of Sp1 induces apoptosis of untrans-
formed cells or cancer cells [17].
To further confirm whether HPB242 could modulate
anti-apoptotic protein expression toward apoptosis, we
observed alterations of Mcl-1 and Survivin when cells
were treated with different doses. Mcl-1, Survivin and cell
cycle regulatory proteins were greatly reduced by HPB242
treatment in a dose dependent manner (Figure 4). Thus,
HPB242 can be said to positively regulate p27 and nega-
tively regulate Cyclin D1, Mcl-1 and Survivin in OSCCs,
resulting in activation of a caspase-dependent apoptosis
pathway through Cleaved-caspase3 and PARP (Figure 5).
In this study, we investigated the cancer chemoprevention
effect of HPB242 on OSCCs. Our results revealed that
HPB242 has cell growth inhibitory activity and induces
apoptosis in OSCCs through inhibition of Sp1 expression.
Taken together, clinical studies with HPB242 are ne-
cessary to explain its unexpected potential toxicity and
clinical applications.
Conclusion
OSCC was influenced by the chemotherapeutic effects
of HPB242. We suggest that HPB242 regulate Sp1 target
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http://www.jbiomedsci.com/content/21/1/4proteins, resulting in apoptosis by the suppression of
Sp1 levels in HN22 and HSC4 cells. Sp1 can be used as
an effective therapeutic target in cancer research, and
HPB242 are potential cancer drugs or adjuvants as che-
motherapeutic agents for OSCC.
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